Samantha Semenkow
Stock Analyst at Citigroup
(0.83)
# 3,694
Out of 4,829 analysts
44
Total ratings
28.57%
Success rate
-21.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Buy | $796 → $803 | $549.27 | +46.19% | 6 | May 9, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $60 | $25.57 | +134.65% | 1 | May 2, 2025 | |
| BIOA BioAge Labs | Maintains: Neutral | $7 → $5 | $4.03 | +24.07% | 3 | Mar 24, 2025 | |
| SLRN Acelyrin | Maintains: Neutral | $6 → $3 | $2.36 | +27.39% | 2 | Jan 7, 2025 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $12 | $3.17 | +278.55% | 1 | Dec 2, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $7 → $8 | $1.16 | +589.66% | 2 | Aug 9, 2024 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $27 → $31 | $23.37 | +32.65% | 2 | Aug 9, 2024 | |
| SANA Sana Biotechnology | Maintains: Buy | $8 → $15 | $1.82 | +724.18% | 2 | Aug 9, 2024 | |
| SNSE Sensei Biotherapeutics | Reinstates: Buy | $4 | $0.36 | +1,011.11% | 2 | Jun 3, 2024 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $10 → $14 | $2.12 | +560.38% | 6 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $1.30 | +669.23% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $1.45 | +934.48% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $4.99 | +140.48% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $30 | $1.19 | +2,421.01% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $38.39 | +87.57% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $14.02 | +256.63% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $17.41 | +221.65% | 3 | Aug 9, 2023 |
argenx SE
May 9, 2025
Maintains: Buy
Price Target: $796 → $803
Current: $549.27
Upside: +46.19%
Structure Therapeutics
May 2, 2025
Initiates: Buy
Price Target: $60
Current: $25.57
Upside: +134.65%
BioAge Labs
Mar 24, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $4.03
Upside: +24.07%
Acelyrin
Jan 7, 2025
Maintains: Neutral
Price Target: $6 → $3
Current: $2.36
Upside: +27.39%
Voyager Therapeutics
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $3.17
Upside: +278.55%
Allogene Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $7 → $8
Current: $1.16
Upside: +589.66%
Catalyst Pharmaceuticals
Aug 9, 2024
Maintains: Buy
Price Target: $27 → $31
Current: $23.37
Upside: +32.65%
Sana Biotechnology
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $1.82
Upside: +724.18%
Sensei Biotherapeutics
Jun 3, 2024
Reinstates: Buy
Price Target: $4
Current: $0.36
Upside: +1,011.11%
Larimar Therapeutics
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $2.12
Upside: +560.38%
May 16, 2024
Upgrades: Buy
Price Target: $10
Current: $1.30
Upside: +669.23%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.45
Upside: +934.48%
Apr 8, 2024
Maintains: Buy
Price Target: $9 → $12
Current: $4.99
Upside: +140.48%
Apr 4, 2024
Maintains: Buy
Price Target: $26 → $30
Current: $1.19
Upside: +2,421.01%
Dec 8, 2023
Initiates: Buy
Price Target: $72
Current: $38.39
Upside: +87.57%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $14.02
Upside: +256.63%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $17.41
Upside: +221.65%